徐潔杰，博士，副研究員，博士生導師。2002年獲四川大學華西醫(yī)學中心（原華西醫(yī)科大學）醫(yī)學學士學位，2005年獲四川大學生命科學學院理學碩士學位，2010年獲復旦大學上海醫(yī)學院醫(yī)學博士學位，之后在復旦大學基礎醫(yī)學院做生物學博士后研究，2012年博士后出站留校任教，先后入選全國優(yōu)秀博士學位論文提名獎、復旦大學“卓學計劃”、上海市"青年科技啟明星"、教育部"新世紀優(yōu)秀人才"。
徐潔杰副研究員長期致力于腫瘤免疫調節(jié)與免疫耐受研究，研究方向為腫瘤免疫逃逸的形成機制。迄今在Gastroenterology、Hepatology、Eur Urol、Nat Commun、Ann Oncol、Clin Cancer Res、Cancer Res、Eur J Cancer、Br J Cancer、Oncoimmunology、Ann Surg、JAMA Surg、Cell Death Differ、Cell Death Dis、J Biol Chem等腫瘤學領域國際權威期刊發(fā)表第一作者和通訊作者SCI論文27篇，其中影響因子10以上的論文達6篇，最高影響因子為20.773。多次受邀為Lancet、Lancet Oncol、Hepatology、J Am Soc Nephrol、Theranostics、Mol Cancer等國際知名腫瘤學期刊審稿。
主要研究方向
腫瘤免疫調節(jié)與免疫耐受、腫瘤免疫逃逸的形成機制
主要承擔課題
課題來源 課題編號
國家自然科學基金 31770851 （面上項目）
國家自然科學基金 81472227 （面上項目）
國家自然科學基金 31270863 （面上項目）
國家科技部 2012ZX10002-012-007 （國家科技重大專項子課題）
上海市科委 13QA1400300 （上海市青年科技啟明星計劃）
教育部 NCET-13-0146 （教育部新世紀優(yōu)秀人才支持計劃）
復旦大學 EZF101354 （復旦大學卓學計劃）
代表性論文列表 (* 為通訊作者)
1、Wang J, Li H, Zhang H, Chen Y, Cao Y, Li R, Lin C, Wei Y, Xiang X, Fang H, Zhang H, Gu Y, Liu X, Zhou R, Liu H, He H, Zhang W*, Shen Z*, Qin J*, Xu J*. Intratumoral IL17-producing cells infiltration correlate with anti-tumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2018 in press (共同通訊作者，IF=13.926)
2、Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J*, Xu J*. Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology. 2018 in press (共同通訊作者，IF=5.503)
3、Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B*, Zhang W*, Xu J*. Tumor-associated macrophage-derived IL-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30718-8. doi: 10.1016/j.eururo.2018.09.030. [Epub ahead of print] (共同通訊作者，IF=17.581)
4、Lin Z, Liu L, Xia Y, Chen X, Xiong Y, Qu Y, Wang J, Bai Q, Guo J*, Xu J*. Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Oncoimmunology. 2018 Aug 6;7(10): e1477461. (共同通訊作者，IF=5.503)
5、Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, Zhou Q, Chang Y, Dai B*, Xu J*. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology. 2018 Aug 1;7(9): e1474317. (共同通訊作者，IF=5.503)
6、Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Fu Q, Dai B, Ye D*, Xu J*. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer. Clin Cancer Res. 2018 Jul;24(13); 3069–78. (共同通訊作者，IF=10.199)
7、Wu S, He H, Liu H, Cao Y, Li R, Zhang H, Li H, Shen Z*, Qin J*, Xu J*. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology. 2018 May 12;7(6):e1433517. (共同通訊作者，IF=5.503)
8、Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J*, Sun Y*. Tumor infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018 Feb;267(2):311-318. (共同通訊作者，IF=9.203)
9、Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H*, Zhang W*, Xu J*. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. JAMA Surg. 2017 Nov 15;152(11):e173120. (共同通訊作者，IF=8.498)
10、Zhu Y, Liu Z, Wang Y, Fu H, Wang Z, Xie H, Zhang J, Li G, Dai B, Xu J*, Ye D*. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncoimmunology. 2017 Aug 8;6(11):e1359450. (共同通訊作者，IF=5.503)
11、Wang J, Lin C, Li H, Li R, Wu Y, Liu H, Zhang H, He H, Zhang W*, Xu J*. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefits in patients with gastric cancer. Oncoimmunology. 2017 Jul 24;6(11):e1353858. (共同通訊作者，IF=5.503)
12、Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, Zhang W, Zhang H, Xu J*, Gu J*. Loss of N-acetylgalactosaminyltransferase-4 orchestrate oncogenic microRNA-9 in hepatocellular carcinoma. J Biol Chem. 2017 Feb 24;292(8):3186-200. (共同通訊作者，IF=4.01)
13、Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, Lin Z*, Xu J*. Tumor infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology. 2017 Feb 21;6(4):e1293211. (共同通訊作者，IF=5.503)
14、Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, Zhang W*, Xu J*. Prognostic Value of Interleukin-6 and Interleukin-6 Receptor in Organ-Confined Clear-Cell Renal Cell Carcinoma: A 5-Year Conditional Cancer-Specific Survival Analysis. Br J Cancer. 2015 Dec 1;113(11):1581-1589. (共同通訊作者，IF=5.922)
15、Liu W, Liu Y, Liu H, Zhang W, Fu Q, Xu J*, Gu J*. Tumor suppressive function of p21-activated kinase 6 in hepatocellular carcinoma. J Biol Chem. 2015 Nov 20;290(47):28489-501. (共同通訊作者，IF=4.01)
16、Liu H, Liu Y, Liu W, Zhang W, Xu J*. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015 Sep 25;6:8494. (通訊作者，IF= 12.353)
17、An H, Xu L, Chang Y, Zhu Y, Yang Y, Chen L, Lin Z*, Xu J*. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2015 Sep;51(14):1953-61. (共同通訊作者，IF=7.191)
18、Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z*, Xu J*. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015 Aug 11;113(4):626-33. (共同通訊作者，IF=5.922)
19、Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, Lin Z, Xu J*. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015 Feb 12;6:e1637. (通訊作者，IF=5.378)
20、Zhang W, Liu H, Liu W, Liu Y, Xu J*. Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-κB pathway. Cell Death Differ. 2015 Feb;22(2):287-97. (通訊作者，IF=8.000)
21、Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q, Xu JJ*, Gu JX*. Decreased Expression of Hnf4α/miR-122 Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Activity. J Biol Chem. 2015 Jan 9;290(2):1170-85. (共同通訊作者，IF=4.01)
22、Zhang H, Wang X, Xu J*, Sun Y*. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer. 2014 Apr 29;110(9):2283-90. (共同通訊作者，IF=5.922)
23、An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu H, Chen L*, Xu J*, Lin Z*. High C-X-C chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br J Cancer. 2014 Apr 29;110(9):2261-8. (共同通訊作者，IF=5.922)
24、He H, Shen Z, Zhang H, Wang X, Tang Z, Xu J*, Sun Y*. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. Br J Cancer. 2014 Apr 15;110(8):2021-9. (共同通訊作者，IF=5.922)
25、Xu J, Liu H (co-first author), Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y*, Gu J*. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology. 2012 Jul;143(1):199-212.e4. (并列第一作者，IF=20.773)
26、Liu H, Xu J (co-first author), Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y*, Gu J*. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011 Dec 15;71(24):7547-57. (并列第一作者，IF=9.130)
27、Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, Liu Y, Wang W, Wen Y*, Gu J*. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010 Jul;52(1):142-54. (第一作者，IF=14.079)
